Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03NCF
|
||||
| Former ID |
DNC013043
|
||||
| Drug Name |
Tyr-Pro-Hfe-Pro-NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C29H37N5O5
|
||||
| Canonical SMILES |
C1CC(N(C1)C(=O)C(CCC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)C(CC4=<br />CC=C(C=C4)O)N)C(=O)N
|
||||
| InChI |
1S/C29H37N5O5/c30-22(18-20-10-13-21(35)14-11-20)28(38)34-17-5-9-25(34)27(37)32-23(15-12-19-6-2-1-3-7-19)29(39)33-16-4-8-24(33)26(31)36/h1-3,6-7,10-11,13-14,22-25,35H,4-5,8-9,12,15-18,30H2,(H2,31,36)(H,32,37)/t22-,23-,24-,25-/m0/s1
|
||||
| InChIKey |
SJJQQBJUOIMODQ-QORCZRPOSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.